Purchase Order 36C24225P1475

Award Date 9/4/25
Potential Completion Date 12/4/25
Potential Value $13K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Belle Isle, FL 32809, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price purchase order contract awarded by the Department of Veterans Affairs (VA) Veterans Health Administration, specifically the Veterans Integrated Service Network (VISN) 2, to Walgreens Specialty Pharmacy, LLC. The contract is for the delivery of the medication Jynarque (tolvaptan) 45/15mg tablets, which is used to treat autosomal dominant polycystic kidney disease. The contract has a ceiling value of $13,242.99 and a performance period ending on June 18, 2025. The...
This is a firm fixed-price purchase order contract awarded by the Department of Veterans Affairs (VA) Veterans Health Administration to Walgreens Specialty Pharmacy, LLC, a subsidiary of the Walgreens retail pharmacy chain. The contract, valued at $83,000.32, is for the supply of the pharmaceutical drug JYNARQUE (tolvaptan) to treat autosomal dominant polycystic kidney disease. The contract does not have a set-aside designation and has an ultimate completion date of September 30, 2021. Walgreens...
This is a firm fixed price purchase order contract awarded by the U.S. Department of Veterans Affairs (VA) Veterans Health Administration (VHA) to Walgreens Specialty Pharmacy, LLC, a division of the Walgreens retail pharmacy chain. The $12,580.72 contract is for the supply of Jynarque 45mg/15mg tablets, a specialty pharmaceutical used to treat autosomal dominant polycystic kidney disease. The contract has a performance period from June 5, 2024 to September 5, 2024 and was not set aside for...
This is a firm fixed-price purchase order awarded by the Department of Veterans Affairs (VA) Veterans Health Administration to Walgreens Specialty Pharmacy, LLC, a subsidiary of the Walgreens retail pharmacy chain. The contract is for the emergency supply of the prescription drug Jynarque (tolvaptan) to the Northport VA Medical Center. The contract has a ceiling value of $13,242.99 and a performance period ending on July 21, 2025. The contract was awarded on July 7, 2025 and does not have a...
This is a $13,242.99 firm fixed-price purchase order awarded by the Department of Veterans Affairs (VA) to Walgreens Specialty Pharmacy, LLC, a subsidiary of the Walgreens retail pharmacy chain. The contract is for the delivery of the medication Jynarque (tolvaptan) to the VA's Veterans Integrated Service Network 2 (VISN 2). The award has no set-aside designation, indicating it is open to all qualified vendors. The performance period runs from the award date of April 30, 2025 through the...
This is a federal contract award with the ID 36C24225P0419, issued by the U.S. Department of Veterans Affairs (VA) to the prime contractor Walgreens Specialty Pharmacy, LLC (doing business as Walgreens). The contract is for the supply of the pharmaceutical product Jynarque (tolvaptan) 45mg/15mg tablets, which is used to treat autosomal dominant polycystic kidney disease. The contract is a firm fixed price purchase order with a ceiling value of $13,242.99 and an ultimate completion date of...
This federal contract award, valued at $12,580.72, was issued by the U.S. Department of Veterans Affairs (VA) Veterans Integrated Service Network 2 (VISN 2) to the prime contractor, Walgreens Specialty Pharmacy, LLC (doing business as Walgreens). The contract is for the delivery of the medication Jynarque (tolvaptan), which is used to treat autosomal dominant polycystic kidney disease. This is a firm fixed-price purchase order with a completion date of February 13, 2025. Walgreens Specialty...
This is a firm fixed-price purchase order contract awarded by the Veterans Integrated Service Network 2 (VISN 2), a civilian agency, to Walgreens Specialty Pharmacy, LLC, a for-profit subsidiary of the Walgreens retail pharmacy chain. The contract, valued at $13,242.99, is for the delivery of the medication JYNARQUE (tolvaptan) to support the healthcare needs of veterans. The contract has an ultimate completion date of October 5, 2025 and was awarded on September 5, 2025. This contract is not...
This is a firm fixed-price purchase order awarded by the Department of Veterans Affairs (VA) to Walgreens Specialty Pharmacy, LLC, a subsidiary of the Walgreens retail pharmacy chain. The contract, valued at $13,242.99, is for the emergency supply of the medication Jynarque (tolvaptan) to VA healthcare facilities. Jynarque is used to treat autosomal dominant polycystic kidney disease. The contract has an ultimate completion date of August 8, 2025 and was awarded on August 4, 2025. There is no...
The U.S. Department of Veterans Affairs (VA) Veterans Health Administration (VHA) awarded a firm fixed price purchase order to Walgreens Specialty Pharmacy, LLC in the amount of $12,580.72. The contract is for the delivery of the medication Jynarque (tolvaptan) to treat autosomal dominant polycystic kidney disease. This contract was awarded to Walgreens Specialty Pharmacy as the prime contractor, with no set-aside designation mentioned. The contract period of performance runs through March 19,...

This is a firm fixed-price purchase order contract awarded by the U.S. Department of Veterans Affairs to Walgreens Specialty Pharmacy, LLC, a subsidiary of the Walgreens retail pharmacy chain. The contract is for the delivery of Jynarque (tolvaptan) 45/15 mg tablets, a medication used to treat autosomal dominant polycystic kidney disease. The contract has a ceiling value of $13,242.99 and a performance period ending on December 4, 2025. The contract was awarded on September 4, 2025 and is not set aside for any specific business type. Walgreens Specialty Pharmacy, LLC is the prime contractor and will be responsible for providing the required pharmaceutical products to the VA's Veterans Integrated Service Network 2.

Generated 9/19/25, 10:58 AM